1. Home
  2. CCSI vs MNPR Comparison

CCSI vs MNPR Comparison

Compare CCSI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consensus Cloud Solutions Inc.

CCSI

Consensus Cloud Solutions Inc.

HOLD

Current Price

$38.70

Market Cap

683.1M

Sector

Technology

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$111.36

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCSI
MNPR
Founded
2021
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
683.1M
587.4M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
CCSI
MNPR
Price
$38.70
$111.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
11
Target Price
$37.50
$107.00
AVG Volume (30 Days)
142.8K
263.1K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.99
EPS
2.72
N/A
Revenue
$349,696,000.00
N/A
Revenue This Year
$3.33
N/A
Revenue Next Year
$2.70
N/A
P/E Ratio
$14.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.20
$29.18
52 Week High
$41.40
$124.82

Technical Indicators

Market Signals
Indicator
CCSI
MNPR
Relative Strength Index (RSI) 57.14 49.18
Support Level $32.75 $102.88
Resistance Level $39.41 $114.60
Average True Range (ATR) 1.87 6.56
MACD 0.08 -1.78
Stochastic Oscillator 93.44 25.29

Price Performance

Historical Comparison
CCSI
MNPR

About CCSI Consensus Cloud Solutions Inc.

Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: